Incyte Corp. buy klostergang
Start price
26.06.17
/
50%
€121.30
Target price
29.10.18
€138.91
Performance (%)
-52.00%
End price
29.10.18
€58.23
Summary
This prediction ended on 29.10.18 with a price of €58.23. Massive losses of -52.00% were the result for the BUY prediction by klostergang. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | -0.399% | -0.399% | 39.442% | 22.396% |
| iShares Core DAX® | -1.742% | -10.677% | -0.889% | 48.094% |
| iShares Nasdaq 100 | -2.583% | -3.319% | 11.124% | 74.134% |
| iShares Nikkei 225® | -1.165% | -9.362% | 23.687% | 48.880% |
| iShares S&P 500 | -1.422% | -3.762% | 7.187% | 57.428% |
Comments by klostergang for this prediction
In the thread Incyte Corp. diskutieren
klostergang stimmt der Buy-Einschätzung von datca zu
klostergang stimmt am 26.06.2017 der Buy-Einschätzung von datca zu.
Überschrift: Incyte Corporation (INCY),-Kooperationen mit Novartis,Eli Lilly,Merck,MedImmune,Bristol-Myers Squibb,Genentech,Pfizer
(Laufzeit überschritten)